成人原发性脑肿瘤再程放疗常规分割剂量约束的前瞻性研究
单机构前瞻性研究评估成人复发原发性脑肿瘤再程放疗的复合剂量约束,20例可评估患者中19例(95%)未出现3级及以上中枢神经系统坏死,中位总生存期13.3个月,提示依据既往剂量分布制定的常规分割再程放疗方案可安全实施。
要点
- 20例可评估患者中19例(95%)未发生3级及以上中枢神经系统坏死。
- 1例在再程放疗后2个月出现3级及以上坏死,完全恢复后生存18个月死于疾病进展。
- 全组中位总生存期13.3个月(95%可信区间6.3-20.7),胶质母细胞瘤患者为11.5个月(95%可信区间6.1-20.1)。
核心结论
- 脑再程放疗采用依据既往剂量分布制定的常规分割方案可安全实施。
- 本文描述的前瞻性复合剂量约束是未来常规分割再程放疗研究的起点。
研究设计与样本
- 单机构前瞻性研究,纳入既往接受过放疗的成人复发脑肿瘤患者,2017年3月至2018年5月入组,20例可评估。
- 对95%的患者获取首程放疗(RT1)电子剂量学记录并形变配准至再程放疗(RT2)模拟CT。
- RT2常规分割治疗计划需满足方案规定的RT2单独剂量约束及RT1+RT2复合剂量约束。
- 前瞻性复合剂量约束基于组织学、距RT1间隔时间及是否联用贝伐珠单抗制定。
- 患者接受包括波谱和灌注成像的磁共振成像随访,主要终点为RT2后6个月症状性脑坏死发生率。
主要发现
- 18例为胶质瘤,1例为非典型脉络丛乳头状瘤,1例为血管外皮细胞瘤。
- 19例接受容积调强弧形治疗,1例接受质子治疗。
- RT1中位剂量57 Gy(范围50-60 Gy),RT1至RT2中位间隔49个月(范围9-141个月)。
- RT2中位剂量42.4 Gy(范围36-60 Gy),中位计划靶区体积186 cc(范围8-468 cc)。
- 20例中19例(95%)未出现3级及以上中枢神经系统坏死;1例在RT2后2个月出现3级及以上坏死,完全恢复后生存18个月直至死于疾病进展。
局限性
- 本文描述的前瞻性复合剂量约束是未来常规分割再程放疗研究的起点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Dose constraints for reirradiation of recurrent primary brain tumors are not well-established. This study was conducted to prospectively evaluate composite dose constraints for conventionally fractionated brain reirradiation. METHODS AND MATERIALS: A single-institution, prospective study of adults with previously irradiated, recurrent brain tumors was performed. For 95% of patients, electronic dosimetry records from the first course of radiation (RT1) were obtained and deformed onto the simulation computed tomography for the second course of radiation (RT2). Conventionally fractionated treatment plans for RT2 were developed that met protocol-assigned dose constraints for RT2 alone and the composite dose of RT1 + RT2. Prospective composite dose constraints were based on histology, interval since RT1, and concurrent bevacizumab. Patients were followed with magnetic resonance imaging including spectroscopy and perfusion studies. Primary endpoint was the rate of symptomatic brain necrosis at 6 months after RT2. RESULTS: Patients were enrolled from March 2017 to May 2018; 20 were evaluable. Eighteen had glioma, 1 had atypical choroid plexus papilloma, and 1 had hemangiopericytoma. Nineteen patients were treated with volumetric modulated arc therapy, and one was treated with protons. Median RT1 dose was 57 Gy (range, 50-60 Gy). Median RT1-RT2 interval was 49 months (range, 9-141 months). Median RT2 dose was 42.4 Gy (range, 36-60 Gy). Median planning target volume was 186 cc (range, 8-468 cc). Nineteen of 20 patients (95%) were free of grade 3+ central nervous system necrosis. One patient had grade 3+ necrosis 2 months after RT2; the patient recovered fully and lived another 18 months until dying of disease progression. Median overall survival from RT2 start for all patients was 13.3 months (95% credible interval, 6.3-20.7); for patients with glioblastoma, 11.5 months (95% credible interval, 6.1-20.1). CONCLUSIONS: Brain reirradiation can be safely performed with conventionally fractionated regimens tailored to previous dose distributions. The prospective composite dose constraints described here are a starting point for future studies of conventionally fractionated reirradiation.
引用
- McGovern SL, Luo D, Johnson J, et al. A Prospective Study of Conventionally Fractionated Dose Constraints for Reirradiation of Primary Brain Tumors in Adults. Pract Radiat Oncol. 2022. PMID: 36596356. doi:10.1016/j.prro.2022.12.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。